Another key objective of the ACT Consortium is to facilitate collaboration between Canadian biotechnology groups and clinical trialists. Since most biotechnologies require RCTs demonstrating efficacy and safety to obtain regulatory approvals in Canada, the objective of this RFA is to fund trials evaluating products from Canadian-controlled biotechnology companies in partnership with ACT Network clinical trialists.
Applicants can request up to $400,000 (CAN) in funding to facilitate phase 2, pilot, or Vanguard trials. Trials that assess safety, recruitment potential, and feasibility are also welcome provided they are an RCT.
Eligibility:
For an application to be eligible, it must fulfill the following criteria.
- Trial must evaluate a biotechnology from a Canadian-controlled biotechnology company.
- The proposal must be an RCT and not a product validation observational study.
- The proposed budget must be CIHR eligible.
Deadline: The deadline to apply is Sunday January 5th, 2025 at 11:59 pm ET
Application Process:
The application portal can be found here: https://redc.phri.ca/redcap/surveys/?s=LDWA7RLTFJWLNNEM
If you have any questions about the applications process, please reach out to us at: ACT.Canada@PHRI.ca
Should you have any questions or require assistance, please reach out by December 20, 2024 to ensure a prompt response. Queries received after this date may not garner a response. |